Research provides evidence that a drug used to slow the progression of the disease ALS shows promise in suppressing the self-renewing cancerous stem cells that challenge the present standards of care ...
Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of real-world data from a retrospective analysis of healthcare resource utilization (HCRU) among people with amyotrophic ...
The presentations will provide insights into patient demographics, treatment duration, progression milestones and healthcare resource utilization data among RADICAVA ORS ® (edaravone)-treated ...